Physician profile
Jo A Witter
NPI 1942239421
$708.86
in general payments reported to CMS, 2019-2025
23 companies · $54.50 in 2025
The $54.50 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.77 · 2020: $141 · 2021: $126 · 2022: $159 · 2023: $59.30 · 2024: $91.48 · 2025: $54.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $205.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $86.48 | 2020-2025 | Ozempic |
| Allergan, INC. | $58.62 | 2020 | |
| Sunovion Pharmaceuticals INC. | $47.69 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $46.13 | 2023-2024 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $44.09 | 2024-2025 | Airsupra |
| Pfizer INC. | $42.50 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $40.16 | 2020-2021 | |
| Lilly USA, LLC | $38.29 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $31.62 | 2020-2021 | |
| Celgene Corporation | $26.53 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.41 | 2019-2022 | |
| Acorda Therapeutics, INC | $25.47 | 2019 | |
| Astellas Pharma US INC | $22.94 | 2023 | Veozah |
| Alkermes, INC. | $22.78 | 2024 | Aristada, Lybalvi |
| Exact Sciences Corporation | $21.26 | 2025 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $20.93 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.33 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.07 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.03 | 2022 | |
| Abbvie INC. | $15.30 | 2024 | |
| Dexcom, INC. | $15.03 | 2023 | Dexcom G6 Transmitter |
| Ultragenyx Pharmaceutical INC. | $14.50 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jo Witter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.